UKRI Translation: MRC Impact Acceleration Awards support academic teams to test one high-risk step in medical intervention development, generating evidence to guide onward development or patient benefit.
The application window changed from 16 July–11 November 2026 to 12 November 2026–10 March 2027. For applications submitted after 1 April 2026, the uninvited-resubmission ban now covers previous submissions to MRC or other UKRI funders, rather than any funder; the application link and eligibility guidance also changed.
UKRI translation: MRC proof of concept: stage two supports academic teams developing and testing medical interventions from prototypes through early clinical trials to advance patient benefit or commercialisation.
MRC: research grant: applicant-led supports research teams pursuing discovery and early translational studies to understand human health and disease and advance diagnosis, treatment and prevention.
UKRI Translation: Impact Acceleration Accounts 2027 supports UK research organisations with flexible funding for early-stage impact activities that translate research into societal, economic and environmental benefits.
MRC: new investigator research grant: applicant-led supports new investigators with discovery and early translational health research to understand disease and build independent research careers.
MRC: partnership grant: applicant-led supports research teams building collaborations, shared resources and capabilities to deepen understanding of human health and disease and underpin future research.